Gilead sets a price for its drug against coronavirus: each treatment will cost more than 2,000 euros.

The first drug against coronavirus to receive the European marketing approval, Remdesivir, already has a price. The company that developed it, the American Gilead, has set its sale price for public health at 390 dollars (about 348 euros) per dose, which means that each treatment could be around 2,340 dollars (about 2,090 euros). This figure would rise to $ 3,120 for private healthcare in the US.

The price of the American biopharmaceutical giant Gilead suffers a new impulse on Wall Street on the way to the 100 billion dollars of capitalization. At the close of last Friday, it concluded with a stock market value of $ 93.54 billion, about 83.5 billion euros.

The start of the week brings up notable news about the Gilead drug that has grabbed all the headlines in recent months: Remdesivir . The company has today set the price for the compound developed to fight the coronavirus.

Gilead will sell Remdesivir to the United States Government and to those of other developed countries at a price of $ 390 (about 348 euros) each dose.

According to the trials developed with the drug, most patients could receive an average of six doses of Remdesivir, so that the total cost of the treatment would amount to $ 2,340 , about 2,090 euros.

This figure will rise by 33% in sales of the drug to private healthcare in the US . In this case, the sale price of each dose will be $ 520 (about 464 euros), and the price of the treatment will amount to $ 3,120.

As reported by the company in a statement, in the US there will be two prices, one of $ 390 for the Public Administration, and the other for private health companies, which will pay $ 520 per dose. Thus, treatment in private centers will amount to $ 3,120 (about 2,785 euros).

The United States is the only country where these two prices will exist due to the nature of the drug market and the health system of the North American country. While governments in other countries negotiate prices directly with pharmaceutical companies, in the US government health programs usually receive state discounts on products sold to the private sector.

Climbs on Wall Street

Successive approval of the drug by the different drug agencies was not the only issue that raised great expectations about Remdesivir. Since its approval by the US agency, the FDA, the market has triggered the debate on its price.

Analysts had warned of the cost in the image that it would have for the biopharmaceutical to set a high sale price of Remdesivir to multiply its benefits amid the biggest health crisis in the United States. But experts also took it for granted that Gilead could generate billions of dollars of revenue in a couple of years if the pandemic persists.

In the midst of the price debate, investors initially reacted with a notable boost to Gilead's listing. The increases reached 3.5% in the pre-opening of Wall Street, a revaluation equivalent to 2,920 million euros in terms of market capitalization, already close to the barrier of 100,000 million dollars.

Thanks to advances in the development of Remdesivir for the treatment of the coronavirus, Gilead's actions have accumulated a clearly bullish balance in recent months. Since the lows recorded in his case at the end of January, a company of the size of Gilead has appreciated more than 20% on Wall Street.